

35

Abstract

Introduction

 ancestry (EUR) individuals. The first modeled shared genetic variance across schizophrenia (SCZ), BD, MDD, posttraumatic stress disorder (PTSD), and anxiety, identifying a single 79 common factor.¹⁶ Across eight psychiatric disorders—attention-deficit hyperactivity disorder,

anorexia nervosa, autism spectrum disorder, BD, MDD, obsessive compulsive disorder, SCZ,

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.09.24307111;](https://doi.org/10.1101/2024.05.09.24307111) this version posted May 10, 2024. The copyright holder for this preprint

 Previous studies have also typically focused on identifying transdiagnostic genetic risk, but gSEM can also enable more precise identification of disorder-specific genetic mechanisms than individual GWAS. In combination with transdiagnostic genetic approaches, GWAS-by-106 subtraction²² can parse associations with single nucleotide polymorphisms (SNPs) into those that influence risk for a disorder through a common genetic factor from those that operate independently of the common factor. The two resulting genetic dimensions can be used to differentiate the associations of a common genetic factor with psychiatric, medical, and social 110 phenotypes from the associations of genetic risk that operates independently of the common factor. Combining transdiagnostic and disorder-level approaches enhances statistical power to detect pleiotropic effects, while identifying patterns of genetic heterogeneity and increasing the 113 specificity of SNP discovery.²³

 To extend previous study findings, we used gSEM to characterize the underlying genetic structure of SUDs, psychotic, and mood and anxiety disorders in EUR and AFR individuals. First, we examined the genetic factor structure of the disorders using exploratory and confirmatory factor analyses, and then we explored each factor's biological underpinnings by conducting GWAS. Next, we investigated the shared genetic comorbidity of SUDs with psychotic, mood, and anxiety disorders using a second-order gSEM approach, which involves examining the relationships between the lower-level factors to identify genetic risks that are shared across factors. Finally, we characterized the common and independent genetic variance for select disorders using GWAS-by-subtraction. Thus, we sought to address two critical gaps in previous research: first, by applying gSEM among AFR individuals, and second, by employing a hierarchical approach to explore both genetic specificity and transdiagnostic genetic risk.

 Prior to common factor modeling in accordance with the procedure for performing gSEM, we calculated genetic correlations between the disorders using linkage disequilibrium 150 score regression (LDSC) implemented in GenomicSEM $0.0.5c$ ¹⁶ To prevent downward bias in LDSC estimates, when SNP-level sample sizes were not available within each set of summary statistics, we calculated the effective sample size using the sum of effective sample sizes across 153 the input GWAS cohorts (see Supplementary Materials).³⁰ For EUR analyses, SNPs were 154 restricted to those contained within the EUR HapMap3 reference panel³¹ with a minor allele frequency (MAF) > 0.01. We then performed LDSC using EUR 1000 Genomes Phase 3 linkage 156 disequilibrium (LD) scores.³² Given the statistical challenges associated with including non-EUR individuals in gSEM analyses due in part to differences in LD structure and admixture, we compared the performance of three sets of LD scores before performing LDSC in AFR 159 individuals. We restricted each set of LD scores to well-imputed SNPs with $MAF > 0.01$ and then compared several parameters, including LD score distribution, LD block length, and the stability of SNP-based heritability and genetic correlation estimates to determine the optimal approach (see Supplementary Materials). This step ensured the selection of an appropriately matched reference panel to avoid biasing estimates. Ultimately, we selected the Pan-UKB AFR 164 reference data,³³ which enabled the best performance of gSEM models among AFR individuals.

Genomic Structural Equation Modeling

 Consistent with best approaches for gSEM, we performed exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) on independent data to evaluate the reliability of our results. We first performed EFA on the odd chromosomes using LDSC matrices derived from the summary statistics of the previously described SUDs and psychiatric disorders to evaluate the optimal number of factors and the loadings of each disorder in a hypothesis-free manner. We

171 used the *Matrix* R package to correct for the possibility of a non-positive definite matrix³⁴ within the LDSC output and then performed EFA for 1-4 latent factors using the *lavaan* R package and 173 a promax rotation.³⁵ Following EFA, we examined model fit indices (i.e., chi-square value, Akaike information criterion (AIC), comparative fix index (CFI), and standardized root mean 175 squared residual (SRMR)) and eigenvalues to determine the optimal model.³⁶ Traits with a 176 loading \geq 0.35 on each latent factor were retained for confirmatory factor analysis (CFA), which was performed on the even chromosomes to avoid overfitting the data. Because of the limited statistical power in AFR models, factor analyses were performed on all chromosomes. Following CFA, we prepared the input summary statistics for GWAS by standardizing coefficients and standard error (SE) values, such that SNP effects were scaled similarly for binary and continuous phenotypes. For quality control, we included only SNPs with MAF>0.01 and imputation score>0.60. In GWAS, we regressed each SNP on each latent variable using diagonally weighted least squares (DWLS) estimation and standard genomic control. We calculated the effective sample size of each resulting common factor GWAS as described by 185 Mallard et al. $(2022).^{37}$ Next, we constructed second-order common factor models to capture genetic effects that

 account for co-occurrence among SUDs and their psychiatric comorbidities. For both the EUR and AFR analyses, to ensure identification of the second-order models, we set the loadings of each first-order factor onto its respective second-order factor equal to the square root of their 190 genetic correlation.³⁸ We then ran GWAS on each second-order factor using the procedure described for the first-order common factor GWAS.

 To identify significant independent SNPs from GWAS, we performed LD clumping with 193 PLINK 1.9³⁹ using an r^2 threshold of 0.1 and physical distance threshold of 3000 kb

 (Supplementary Materials). For loci not previously significantly associated with a corresponding SUD, psychotic, mood, or anxiety disorder (hereafter referred to as novel), we performed PheWAS on the lead SNP to examine its associations across the phenomic spectrum using the 197 GWAS Atlas (Supplementary Materials).⁴⁰ Additionally, for any novel lead SNPs identified, we used the LD-based Probabilistic Identification of Causal SNPs (PICS) v2.1.1 finemapping tool to assess their potential as the most likely causal variant to be responsible for the observed association in a given locus.

 After performing each of the first- and second-order common factor GWAS, we 202 calculated Q_{SNP} , a measure of heterogeneity that tests the null hypothesis that a SNP's effects operate entirely through a common factor. For example, a SNP that primarily influences SUDs through its effects on a single disorder, like TUD, should violate the null hypothesis. To identify SNPs with heterogeneous effects, we examined associations between each SNP and common factor via a common pathway model. Then, separately for each factor, we fit an independent pathway model in which the SNP predicted each of the factor's indicators. We performed a chi- square difference test on the two models (Supplementary Figure 1) and removed SNPs with *p* < 5 $x 10^{-8}$ (Supplementary Tables 6-10) from the factor's summary statistics prior to conducting all post-GWAS analyses.

GWAS-by-Subtraction

 To ensure that the GWAS-by-subtraction models were informative and adequately powered, we performed these analyses only on disorders with a standardized unexplained 214 variance > 0.30 in the first-order CFA. Following the paradigm of Demange et al. (2021),²² we first specified two latent genetic factors. On the first factor, we loaded only the specific disorder of interest (i.e., depending on the model, TUD, BD, or SCZ), while on the other factor we loaded

217 the specific disorder *and* the other disorders included in its broader common factor. Then, we 218 imposed two constraints by setting to 0 the covariance between: (1) the disorder of interest and 219 all other disorders, and (2) the two latent genetic factors. Finally, to capture genetic effects on the 220 disorder that were not correlated with the common factor, we regressed each SNP on the latent 221 factor with a sole loading for the disorder of interest. To identify genetic effects on the disorder 222 of interest that operated through the common factor, each SNP was regressed on the latent factor 223 on which all common factor traits were loaded. Due to the limited statistical power of the AFR 224 models (max N_{eff} = 6,421), we restricted GWAS-by-subtraction analyses to EUR models. The 225 effective sample size calculations for each of the GWAS-by-subtraction models were adjusted to 226 account for the fact that the GWAS modeled residual heritability.²²

227 **Biological Characterization**

228 We used Functional Mapping and Annotation of Genome-Wide Association Studies 229 (FUMA) version $1.6.0^{41}$ to conduct post-GWAS analyses of each GWAS (i.e., first-order 230 common factors in EUR and AFR individuals, second-order common factors in EUR and AFR 231 individuals, and GWAS-by-subtraction models in EUR individuals). Gene-based tests, gene-set 232 enrichment, and gene-tissue expression analyses were conducted using MAGMA version 1.08.⁴² 233 We examined gene expression in BrainSpan⁴³ and GTEx $v8^{44}$ tissue samples. SNP-to-gene 234 associations and gene annotations were evaluated using: (1) expression quantitative trait loci 235 (eQTLs) from PsychENCODE⁴⁵ and GTEx $v8^{44}$ brain tissue samples and (2) chromatin 236 interactions via Hi-C data for the dorsolateral prefrontal cortex, hippocampus, ventricles, and 237 neural progenitor cells.⁴⁶ To annotate the protein products and investigate protein-protein 238 interactions of MAGMA-identified genes, we used the STRING database v12.0 and applied its 239 default parameters.⁴⁷ Enrichment of protein-protein interactions was calculated as the observed

 number of edges (i.e., interactions) divided by the expected number of edges in the protein network. Significant enrichment would suggest that the proteins that are encoded by genes

associated with a factor participate in common pathways relevant to that factor.

Genetic Correlations with gSEM Factors

 Genetic correlations between gSEM output summary statistics and other traits were 245 calculated using LDSC^{48,49} with 1000 Genomes Project phase 3^{32} (for EUR) and PanUKB³³ (for AFR) data as LD references. For first- and second-order common factors in EUR individuals, we 247 used the Complex-Traits Genetics Virtual Lab⁵⁰ to calculate batch genetic correlations with 1,437 traits across a wide variety of domains assessed via International Classification of Diseases (ICD) codes and self-report. In AFR individuals, genetic correlations were calculated for selected psychiatric and medical phenotypes as the Complex-Traits Genetics Virtual Lab does not currently facilitate LDSC in non-EUR ancestries. For GWAS-by-subtraction models in EUR individuals, we calculated genetic correlations with a selection of relevant psychiatric, social, and physical traits to facilitate comparison of the common and independent genetic effects associated with each disorder. We applied a Benjamini-Hochberg false discovery rate (FDR) correction to each set of genetic correlation analyses to account for multiple testing. Lastly, we calculated trans-ancestry genetic correlations using the regression fit method to compare gSEM 257 common factors across EUR and AFR ancestry individuals with Popcorn $v1.0⁵¹$ and ancestry- matched 1000 Genomes reference files. Reference files were prepared by excluding the MHC region, and Popcorn was used to compute LD scores for both populations.

Polygenic Score-Based PheWAS

 Prior to calculating polygenic scores (PGS) in the Penn Medicine Biobank (PMBB), GWAS for the first-order, second-order, and TUD GWAS-by-subtraction models were re-run

 excluding PMBB to ensure independence of the GWAS and target samples. We calculated PGS 264 from gSEM output summary statistics using $PRS-CSx^{52}$ and conducted a phenome-wide association study (PheWAS) in the PMBB. PheWAS is a hypothesis-free approach to explore the association between genetic variants and traits across the spectrum of human disease and health. PMBB participants are recruited through the University of Pennsylvania Health System and 268 provide access to their electronic health record (EHR) and blood or tissue samples.⁵³ Genotyping was performed using the Illumina Global Screening Array. Quality control procedures included removing SNPs with marker call rates <95% and sample call rates <90%, as well as individuals with sex discrepancies. Imputation was performed using Eagle2 (Reference-based phasing using the Haplotype Reference Consortium panel) and Minimac4 on the TOPMed Imputation Server. 273 In the case of related individuals (pi-hat threshold \geq 0.25), one from each pair was removed from analyses. Genetic ancestry was determined using quantitative discriminant analysis of 275 principal components (PCs) using smartpca.^{54,55} These procedures resulted in 10,383 AFR individuals and 29,355 EUR individuals for inclusion in the PheWAS. ICD-9 and ICD-10 codes were gathered from EHR and mapped to phecodes. Cases were individuals with at least two instances of a given ICD code ("phecodes"). PGS were standardized, and PheWAS was conducted by fitting a logistic regression predicting each phecode from the PGS, with sex, age, and the top 10 PCs included as covariates using the *PheWAS* package⁵⁶ in R. We used a Benjamini-Hochberg FDR corrected p-value to ascertain significant associations. **Results**

Genetic Correlations among Input GWAS

[Figure 2 here]

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.09.24307111;](https://doi.org/10.1101/2024.05.09.24307111) this version posted May 10, 2024. The copyright holder for this preprint

 misspecification or overfitting the data, we proceeded with the 2-factor CFA model, which had 355 an adequate fit $(\chi^2(19) = 21.49, p = 0.31, \text{AIC} = 55.49, \text{CFI} = 0.99, \text{SRMR} = 0.10)$ and required no constraints (Figure 2 and Supplementary Table 21). The SUD factor GWAS (Supplementary Figure 10) identified 1 lead SNP, rs1944683, positioned within an intergenic region on chromosome 11. To our knowledge, this variant has not previously been GWS or in LD with any GWS SNPs in AFR GWAS of substance use traits. However, the locus has been associated with alcohol consumption, tobacco-related traits, opioid 361 use disorder, and cannabis use disorder in EUR and cross-ancestry studies.⁶⁴⁻⁶⁶ The SNP exhibited chromatin interaction with two genes: *BLID* and *C11orf63*. A PheWAS of the lead SNP in the GWAS Atlas identified significant associations with regular smoking, past-month stomach pain, and tobacco-related conditions, such as atrial fibrillation and respiratory function (i.e., 365 forced vital capacity and peak expiratory flow). One lead Q_{SNP}, rs10489130, identified on chromosome 4, exhibited significant associations with AUD only and was GWS in a previous AUD GWAS in AFR individuals, suggesting that this SNP may display specificity for AUD 368 rather than influencing SUDs broadly.⁶⁶ For the SUD factor, gene expression was significantly enriched in brain tissues involved in emotion processing, reward signaling, and cognitive control, including the putamen, amygdala, caudate, and hippocampus (Supplementary Figure 11). No significant variants were identified for the psychiatric disorders factor (Supplementary Figure 12). Gene expression was also not significantly enriched for any developmental stage or tissue type, although the top associations were with brain tissues (Supplementary Figure 13). **Second-Order Common Factors**

 Genetic risk shared among SUD and psychotic disorders implicated several gene sets, including molecular functions such as transcription regulation and sequence-specific DNA binding, and biological processes such as neuron differentiation. Genetic risk shared between SUDs and mood disorders was associated with enrichment in two gene sets involved in the biological processes of mechanosensory behavior and axonal protein transport. For both second- order factors, gene expression was enriched in brain tissues (Supplementary Figures 17 and 18). Genes associated with both second-order factors were significantly enriched for protein-protein 397 interactions (SUDs and psychotic disorder $= 1.54x$, SUDs and mood/anxiety disorders $= 1.57x$; $ps < 1.00 \times 10^{-16}$).

27). Chromatin interaction mapping identified several genes on chromosome 6, including the

ZSCAN and *HIST1H* gene families, as possible sources of functional effects related to SCZ risk

- independent of BD (Supplementary Figure 23). Although after Bonferroni correction no gene-
- sets were significantly enriched for SCZ Independent, the top set involved up-regulated genes in
- 425 the prefrontal cortex in mouse models of 22q11.2 microdeletions, which, in humans, are
- 426 associated with risk of developing $SCZ⁶⁷$ Finally, there were 189 significant lead SNPs for BD
- Common and 13 for BD Independent, 10 of which did not reach significance in the BD Common
- GWAS (Supplementary Table 28). Although few SNPs were significant in the BD Independent
- GWAS, chromatin interactions identified potential functional effects of these variants on genes,
- 430 including *MXI1*⁶⁸ and *ADD3*,⁶⁹ which have been previously associated with BD (Supplementary
- Figure 24). For BD Independent, one gene-set involved in the regulation of trans-synaptic
- signaling remained significant after Bonferroni correction. Protein-protein interactions were
- 433 significantly enriched for TUD, SCZ, and BIP Independent (TUD = $3.31x$, $p = 3.45x10^{-13}$, SCZ
- 434 = 5.48x, $p < 1.00 \text{ x } 10^{-16}$, BIP = 5.75x, $p = 2.19 \text{ x } 10^{-11}$), indicating potential molecular
- mechanisms with enhanced specificity (Supplementary Figures 25-27).
-

IFigure 4 here]

Genetic Correlations with gSEM Factors

 European Ancestry. The SUD factor was, as expected, strongly genetically correlated with smoking and alcohol traits, as well as depression and socioeconomic factors, including reduced educational attainment, unemployment due to sickness/disability, and the Townsend deprivation index (Supplementary Figure 28). The psychotic factor correlated most strongly with related traits, such as SCZ, BD, depression, and anxiety. However, psychotic disorders also exhibited a positive genetic correlation with risk taking and a negative correlation with cognitive performance, which consists of fluid intelligence and the first principal component of scores on

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.09.24307111;](https://doi.org/10.1101/2024.05.09.24307111) this version posted May 10, 2024. The copyright holder for this preprint

 neuropsychological tests (Supplementary Figure 29). Although the mood disorders factor correlated most strongly with measures of depression and anxiety, the remaining correlations were predominantly with somatic conditions, such as chronic pain, longstanding illness/disability/infirmity, and prescription medication usage (Supplementary Figure 30). For the second-order factors, the top genetic correlations were a mixture of SUD-related, psychiatric, and medical traits. The SUD and psychotic disorders factor, for example, correlated most strongly with SCZ and BD. Other significant genetic correlations included smoking-related traits, cognitive measures, and risk taking, as with the first-order psychotic disorder factor. The SUD and mood disorders factor correlated most strongly with mood and anxiety traits and illness and medication use for pain or gastrointestinal problems, reflecting similar associations observed for the first-order mood disorders factor (Figure 5). Genetic correlations underscored differences between disorder-level and transdiagnostic genetic effects (Figure 4). Although TUD Common was significantly positively genetically 458 correlated with SCZ (r_g = 0.35, SE = 0.02, p < 0.001), TUD Independent was not (r_g = -0.05, SE $= 0.03, p = 0.08$, with a similar pattern observed for other thought/psychotic disorders. SCZ 460 Common had a nominally weaker negative genetic correlation with cognitive performance $(r_g = -1)$ 461 0.09, $SE = 0.02$, $p < 0.001$) and was significantly positively correlated with educational 462 attainment ($r_g = 0.11$, SE = 0.02, $p < 0.001$), while SCZ Independent had consistently negative 463 associations with both (r_g = -0.22, SE = 0.03, p < 0.001 and r_g = -0.09, SE = 0.02, p < 0.001, respectively). Among other traits, BD Common and Independent showed opposite patterns of associations with automobile speeding propensity and cognitive performance, both of which 466 were negative for BD Common ($r_g = -0.21$, SE = 0.02, $p < 0.001$; and $r_g = -0.24$, SE = 0.02, $p <$ 467 0.001, respectively) and positive for BD Independent ($r_g = 0.13$, SE = 0.03, $p < 0.001$; and $r_g =$

468 0.05, $SE = 0.02$, $p = 0.03$, respectively). SCZ and BIP Independent had significantly different 469 associations with risk-taking ($r_g = 0.25$, $SE = 0.03$, $p < 0.001$ vs. $r_g = -0.04$, $SE = 0.03$, $p = 0.14$; 470 $Z = 6.84$, $p = 8.18 \times 10^{-12}$ and MDD ($r_g = 0.35$, SE = 0.03, $p < 0.001$ vs. $r_g = -0.04$, SE = 0.03, *p* 471 = 0.22 ; Z = 9.19, $p = 3.84 \times 10^{-20}$.

 African Ancestry. The psychiatric disorders factor was genetically correlated with all 11 traits examined, and the SUD factor was significantly correlated with all except PTSD. There were minimal differences between the genetic correlations for the first-order factors, likely due to the large variance in estimates resulting from low statistical power (Supplementary Figure 31). The second-order SUD and psychiatric factor correlated significantly with all traits except PTSD, and the strongest correlations were with smoking trajectory, OUD, depression, and maximum alcohol consumption (Supplementary Figure 32). *Trans-ancestry.* The EUR SUD factor was significantly genetically correlated with the

480 AFR SUD factor ($r_g = 0.730$, SE = 0.094, $p = 0.004$). Similarly, the AFR psychiatric disorders 481 factor was genetically correlated with both the EUR psychotic factor ($r_g = 0.471$, SE = 0.216, *p* = 482 0.014) and the EUR mood disorders factor $(r_g = 0.571, SE = 0.204, p = 0.035)$.

[Figure 5 here]

PheWAS in Penn Medicine BioBank

 European Ancestry. Among participants in PMBB, the SUD factor was associated with TUD, tobacco-related illnesses (lung and other respiratory system cancers and chronic airway obstruction), and mood/anxiety disorders (Supplementary Figure 33 and Supplementary Table 29). The psychotic disorders factor was significantly associated only with psychiatric traits, including BD and mood/anxiety disorders (Supplementary Figure 34 and Supplementary Table 30). In contrast, although the mood disorders factor was most strongly associated with the

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.09.24307111;](https://doi.org/10.1101/2024.05.09.24307111) this version posted May 10, 2024. The copyright holder for this preprint

 presence of various mood and anxiety disorders, it was also associated with physical health conditions like pain, sleep disorders, and obesity (Supplementary Figure 35 and Supplementary Table 31).

 The second-order SUD and psychotic disorders factor was significantly associated with tobacco and alcohol-related disorders, with a nonsignificant association with BD (Supplementary Figure 36 and Supplementary Table 32). Although the PheWAS of the SUD and mood disorders factor revealed the strongest associations with substance use and psychiatric disorders, it also showed significant associations with pain, type 2 diabetes, ischemic heart disease, hypertension, 499 and sleep disorders, amongst other physical health conditions (Supplementary Figure 37 and Supplementary Table 33).

 PheWAS further highlighted the enhanced specificity of the GWAS-by-subtraction models. Although the TUD Common factor was associated with multiple SUDs, the TUD Independent factor demonstrated greater specificity, having the highest associations with TUD and related medical conditions, such as chronic airway obstruction (Supplementary Figure 38). PheWAS for SCZ Common factor showed broad associations with mood disorders, including BD, but there were no significant associations for SCZ Independent (Supplementary Figure 39). PheWAS of both the BD Common and Independent PRS showed significant associations with BD and other mood disorders, but the association with depression was only significant for BD Independent (Supplementary Figure 40).

 African Ancestry. Although there were no statistically significant phenotypic associations among AFR individuals in PMBB, the top hits generally aligned with the factor being examined. For example, the SUD factor was most strongly associated with TUD, followed by SUDs broadly (Supplementary Figure 41 and Supplementary Table 34). Among the top associations for

 the psychiatric factor were generalized anxiety disorder and the "other mental disorder" phenotype (Supplementary Figure 42 and Supplementary Table 35). Similar results were seen for the second-order SUD and psychiatric factor, which included TUD, alcohol-related disorders, and mood disorders within the top associations (Supplementary Figure 43 and Supplementary Table 36).

Discussion

 Leveraging the largest available GWAS in European- and African-ancestry individuals, we combined complementary multivariate methodologies to examine the shared genetic architecture across SUDs, psychotic, mood, and anxiety disorders. We also examined genetic effects that operate independent of the shared genetic risk to influence disorders. By integrating transdiagnostic and disorder-level gSEM, we identified potential biological mechanisms that contribute to comorbidity across disorder classes and those that distinguish commonly co- occurring conditions. Our findings revealed both pervasive pleiotropy across SUDs and other psychiatric disorders *and* trait-specific associations, while also highlighting the need to increase representation of non-European ancestry individuals in genetic studies of mental health.

Identification of SUDs, Psychotic, and Mood Disorder Factors

530 Consistent with other psychiatric genetic findings, $19,70$ we identified common genetic factors underlying disorders that exhibit shared features. As expected, MDD and anxiety, which are highly comorbid and share similar symptoms, loaded onto the same factor. Additionally, across ancestries, common genetic risk partially accounted for the shared features of BD and SCZ. Other gSEM studies have also showed that SCZ and BD load onto the same genetic 535 factor,^{18,70-72} highlighting their strong shared etiology despite belonging to different diagnostic classes. Although smaller samples and greater genetic diversity limited statistical power to

 replicate the EUR factor structure in AFR individuals, there were significant commonalities across genetic ancestry groups. For example, in both AFR and EUR models, SUDs loaded onto a single factor that was highly genetically correlated with a previously identified genetic addiction $\frac{19}{3}$ Additionally, trans-ancestry genetic correlations highlighted the consistency of the genetic influences on the AFR psychiatric disorders factor with both the EUR psychotic and mood disorders factors.

 In AFR individuals, we identified a lead SNP (rs1944683) associated with SUDs that had not been previously GWS or in LD with GWS SNPs in AFR substance-related GWAS. This locus has, however, been previously implicated in alcohol, tobacco, cannabis, and opioid-related 546 traits in EUR and cross-ancestry GWAS.⁶⁴⁻⁶⁶ Our ability to identify this lead SNP was facilitated by the use of gSEM, which allowed us to leverage power across multiple SUDs. In doing so, we were able to overcome some of the limitations posed by the relatively low statistical power of existing GWAS in AFR populations. However, despite statistical advancements, our study remained underpowered in AFR individuals.

 In EUR individuals, we detected two significant loci for the mood and anxiety disorders factor that had not been previously significant in GWAS of mood or anxiety disorders. Performing chromatin interaction mapping on the lead SNPs for these loci implicated genes involved in immune and stress responses (*BTLA* and *NECTIN3*, respectively) and a gene related 555 to hippocampal development (*FOXP1*).^{58,60,62,73} The identification of *BTLA*, which encodes the B- and T-lymphocyte attenuator protein, is consistent with other research highlighting the role of 557 immune dysregulation in psychiatric pathogenesis.⁷⁴⁻⁷⁶ NECTIN3 encodes a cell adhesion molecule that is involved in synaptic plasticity, enriched in hippocampal neurons, and implicated 559 in stress-related disorders. $61,62,77$ FOXP1, a transcription factor that plays a crucial role in

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.09.24307111;](https://doi.org/10.1101/2024.05.09.24307111) this version posted May 10, 2024. The copyright holder for this preprint

560 hippocampal development, has also been implicated in the regulation of synaptic plasticity.⁵⁸ Further highlighting the potential role of immune functioning, these loci have previously been implicated in GWAS of lymphocyte and leukocyte counts, as well as autoimmune conditions, such as inflammatory bowel disease. Thus, dysfunctions in synaptic plasticity and immune 564 regulation may underlie a range of psychiatric conditions, including MDD and anxiety.^{78,79} Targeting these common biological pathways could lead to the development of therapeutics with broader efficacy profiles.

 In EUR individuals, both the SUD and psychotic disorder factors showed a significant association with genes expressed in brain tissue during prenatal development. Although no developmental stage reached significance for mood disorders or in AFR individuals, the top associations were consistently prenatal periods. This underscores the importance of early neurodevelopmental processes, including neurogenesis, synaptogenesis, and the formation of neurotransmitter systems, in shaping the susceptibility to SUDs and psychiatric disorders. Furthermore, prenatal development may represent a sensitive window during which genetic and 574 environmental factors interact to influence long-term mental health outcomes.⁸⁰ Epigenetic 575 mechanisms, such as those modulated by maternal stress and other environmental conditions, $81,82$ may play a crucial role in mediating gene expression patterns and contributing to the developmental origins of psychiatric disorders. The specifics of these epigenetic mechanisms and other non-coding regulatory processes remain largely unclear. However, statistical and technological advances, such as next-generation sequencing and multi-omics analysis, show 580 promise for furthering knowledge in this area.

SUDs Share Genetic Liability with Psychotic and Mood Disorders

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.09.24307111;](https://doi.org/10.1101/2024.05.09.24307111) this version posted May 10, 2024. The copyright holder for this preprint

 Evaluating shared genetic variance across the common factors revealed higher-order dimensions of liability to psychopathology, including genetic risk shared between SUDs and psychotic disorders and between SUDs and mood/anxiety disorders. A PheWAS in the PMBB showed broad phenotypic manifestations of these dimensions of genetic liability. Notably, in EUR individuals, SUD and mood/anxiety disorders exhibited significant associations with various physical health conditions, including obesity, type 2 diabetes, chronic pain, chronic airway obstruction, heart disease, hypertension, and sleep disorders. Because the PheWAS was underpowered in AFR individuals, there were no significant associations, though the top associations included relevant phenotypes, such as alcohol-related disorders, TUD, and mood disorders.

 Genetic correlations further underscored the pervasive impact of genetic risk for psychiatric comorbidities and SUDs. The second-order factors (i.e., SUD and mood disorders and SUD and psychotic disorders) were genetically correlated with adverse outcomes that included lower cognitive performance, elevated HDL cholesterol, chronic pain, long-standing illness, and miserableness. In AFR individuals, the second-order factor, representing shared genetic effects across SUDs and psychiatric disorders, was significantly genetically correlated with pain intensity and various substance use and psychiatric phenotypes. Thus, genetic risk for co-occurring SUDs and psychiatric disorders has far-reaching implications for both mental and physical health.

 In addition to shared variance, in EUR individuals there was substantial unique genetic 602 variance for both psychotic $(0.63, SE = 0.05)$ and mood/anxiety disorders $(0.56, SE = 0.04)$. The residual genetic variance in SUDs was also significant, albeit smaller, after accounting for 604 genetic variance shared with psychotic and mood/anxiety disorders $(0.19, SE = 0.04)$. In EUR

 individuals, more of the genetic variance in SUDs was shared with mood/anxiety than psychotic disorders. This suggests that there are different degrees of genetic convergence between SUDs and their common psychiatric comorbidities. Evaluating these patterns of genetic overlap and heterogeneity can help distinguish highly comorbid psychiatric disorders and pinpoint both shared and distinct etiological mechanisms.

Specificity of Genetic Effects for Tobacco Use Disorder, Schizophrenia, and Bipolar

Disorder

 To evaluate transdiagnostic and disorder-level liability, SNPs for TUD, SCZ, and BD were parsed into effects that: (1) operated through their respective common factors or (2) were uncorrelated with the common factor. Thus, we were able to distinguish biological mechanisms and genetic correlates that contribute to comorbidity across disorders from those that show greater specificity. This hierarchical approach can yield genetic knowledge across levels of psychopathology and identify patterns of convergence and divergence across disorders. As an example of the utility of this approach, GWAS-by-subtraction findings provided insights into the underlying structure of psychotic disorders. SCZ and BD shared a common genetic core, consistent with their shared psychotic features and in line with empirical 621 nosological models.⁸⁴ However, the genetic risk for each disorder that was independent of this common psychotic core showed different patterns of associations with other complex traits. For example, SCZ Independent was more negatively genetically correlated with measures of cognition and educational attainment than BD Independent, which was more strongly associated with risk-taking behaviors and affective disorders. Our results are highly consistent with the expanded psychosis continuum hypothesis, which proposes that although SCZ and BD share a 627 psychotic core, cognitive and affective domains differentiate the disorders.⁸⁵ Specifically, SCZ is

 characterized by greater cognitive impairments and BD by greater affective impairments. Our findings lend genetic support to this hypothesis, previously investigated using only psychological 630 and neural evidence.⁸⁵

 PheWAS results further showcased the enhanced specificity of findings when independent PGS for TUD, SCZ, and BD were compared with transdiagnostic liability. For example, TUD Independent exhibited several associations not observed for the TUD Common factor, including ischemic heart disease, atherosclerosis, obesity, and skin conditions. This may reflect a combination of unhealthy lifestyle factors, direct physiological effects of tobacco use, and shared biological pathways underlying these conditions. This finding is also consistent with epidemiologic and genetic research supporting tobacco use as one of the strongest risk factors for 638 cardiovascular disease.⁸⁶⁻⁸⁸ Differential patterns also emerged for SCZ and BD, with SCZ Common and BD Independent showing broader associations with mood disorders than their respective components. Recent research comparing transdiagnostic and disorder-specific genetic effects across 11 psychiatric disorders similarly observed substantial differences in genetic 642 associations, as has research parsing alcohol-specific risk from broader externalizing liability. 90 Thus, hierarchical genetic approaches can facilitate a more nuanced understanding of patterns of comorbidity and heterogeneity across co-occurring conditions.

 These findings also pave the way for developing more refined PGS than are currently available. For example, depression PGS show little specificity, accounting for a similar amount 647 of variance in mood disorders, anxiety disorders, ADHD, and SUDs.⁹¹ Similarly, an evaluation of 16 PGS for psychiatric phenotypes found that most were associated with general 649 psychopathology rather than the specific domain for which they purported to measure risk.⁹² 650 Although PGS have shown clinical utility in predicting some non-psychiatric disorders, $93,94$

651 prediction performance for psychiatric phenotypes remains limited.⁹⁵ This may be due in part to a lack of specificity of currently available psychiatric PGS. Existing PGS are useful for providing a broad overview of genetic predispositions to psychiatric disorders. However, when the focus shifts to exploring associations of a given psychiatric disorder without the confounding influence of co-occurring conditions, a more granular PGS is needed. Efforts to develop more precise PGS, including via the combined application of transdiagnostic and disorder-level genetic methods, may ultimately enhance their clinical utility.

Conclusions

 Using a combination of multivariate approaches across multiple ancestral groups, we examined the common and independent genetic effects on SUDs, psychotic, mood, and anxiety disorders. In doing so, we identified potential biological mechanisms contributing to comorbidity both within and across classes of disorders, while also identifying pathways that may distinguish commonly co-occurring conditions. Isolating transdiagnostic genetic risk factors from those exhibiting greater specificity may aid in enhancing the precision of genetic prediction, as we observed when comparing genetic correlations and phenotypic associations of genetic risk factors. Thus, integrating transdiagnostic and disorder-level genetic models both clarifies the biological underpinnings of psychiatric comorbidity and identifies distinct biological pathways that contribute to heterogeneity within classes of psychiatric conditions.

 In addition to advancing our understanding of the genetic architecture of SUDs and other psychiatric disorders, our study also highlights the importance of inclusivity in genetic research. 671 Previous gSEM studies have been limited to European-ancestry individuals, ^{16,96,97} but as gSEM has shown the potential to uncover novel genetic associations and provide greater insights into the etiology of complex traits and diseases, it is imperative that these advances be made available

- to individuals of all ancestral backgrounds. Unfortunately, in combination with smaller samples,
- lower LD and higher genetic diversity among African-ancestry individuals present statistical
- 676 challenges for many existing analyses.⁹⁸ This is further complicated by the high degree of
- 677 admixture present among individuals of non-European ancestries within the United States.⁹⁹
- Accurate consideration of population substructure via the use of large, representative reference
- panels is essential for advancing genetic discovery. We provide details (Supplementary
- Materials) on the efforts we took to ensure the inclusion of African-ancestry individuals despite
- present limitations in the hopes that this may aid researchers faced with similar decisions.
- Advancing genetic discovery across diverse populations will be key in shaping our
- understanding of psychiatric etiology.
-

Acknowledgements

 This study is supported by NIH grants K01AA028292 (R.L.K.), R01MH125938 (R.E.P.), P50AA022537 (R.E.P.), T32 HG009495 (K.L.F.), the Brain & Behavior Research Foundation NARSAD grant 28632 PS Fund (R.E.P.), the California Tobacco-Related Disease Research Program (TRDRP; T32IR5226) (S.S-R), the Department of VA Office of Research and Development grants IK2 CX002336 (E.E.H.), I01 BX003341 (H.R.K.) and the Veterans Integrated Service Network 4 Mental Illness Research, Education and Clinical Center. This publication does not represent the views of the Department of VA or the United States Government. We acknowledge the Penn Medicine BioBank (PMBB) for providing data and thank the patient- participants of Penn Medicine who consented to participate in this research program. We would also like to thank the Penn Medicine BioBank team and Regeneron Genetics Center for providing genetic variant data for analysis. The PMBB is approved under IRB protocol #813913 and supported by the Perelman School of Medicine at the University of Pennsylvania, a gift from the Smilow family, and the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA award number UL1TR001878.

701 **Table 1. Genome-wide association studies from which summary statistics were obtained.**

Note: MDD = Major Depressive Disorder, ANX = Anxiety Disorders, SCZ = Schizophrenia, BD = Bipolar Disorder, AUD = Alcohol Use Disorder, CanUD = Cannabis Use Disorder, TUD = Tobacco Use Disorder, OUD = Opioid Use Disorder. See Supplementary Tables 1-4 for full description of cohorts.

*Summary statistics were jointly analyzed using MTAG to enhance the statistical power of the ANX phenotype prior to their being used in gSEM (see Supplementary Materials).

736 **Figure 2.**

739 **Figure 3.**

740 741

Figure 5.

- 23. Waszczuk, M.A. *et al.* Dimensional and transdiagnostic phenotypes in psychiatric genome-wide association studies. *Molecular Psychiatry* (2023).
- 24. Kember, R.L. *et al.* Genetic underpinnings of the transition from alcohol consumption to
- alcohol use disorder: Shared and unique genetic architectures in a cross-ancestry sample.
- *American Journal of Psychiatry* **180**, 584-593 (2023).
- 25. Bigdeli, T.B. *et al.* Genome-wide association studies of schizophrenia and bipolar
- disorder in a diverse cohort of US veterans. *Schizophrenia Bulletin* **47**, 517-529 (2020).
- 26. Otowa, T. *et al.* Meta-analysis of genome-wide association studies of anxiety disorders.
- *Molecular Psychiatry* **21**, 1391-1399 (2016).
- 27. Purves, K.L. *et al.* A major role for common genetic variation in anxiety disorders. *Molecular Psychiatry* **25**, 3292-3303 (2020).
- 28. Levey, D.F. *et al.* Bi-ancestral depression GWAS in the Million Veteran Program and
- meta-analysis in >1.2 million individuals highlight new therapeutic directions. *Nature Neuroscience* **24**, 954-963 (2021).
- 29. Turley, P. *et al.* Multi-trait analysis of genome-wide association summary statistics using MTAG. *Nature Genetics* **50**, 229-237 (2018).
- 30. Grotzinger, A.D., Fuente, J.d.l., Privé, F., Nivard, M.G. & Tucker-Drob, E.M. Pervasive downward bias in estimates of liability-scale heritability in genome-wide association
- study meta-analysis: A simple solution. *Biological Psychiatry* **93**, 29-36 (2023).
- 31. The International HapMap 3 Consortium. Integrating common and rare genetic variation in diverse human populations. *Nature* **467**, 52-8 (2010).
- 32. The 1000 Genomes Project Consortium. A global reference for human genetic variation.
- *Nature* **526**, 68-74 (2015).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.09.24307111;](https://doi.org/10.1101/2024.05.09.24307111) this version posted May 10, 2024. The copyright holder for this preprint

- 33. Pan-UKB Team. [https://pan.ukbb.broadinstitute.org.](https://pan.ukbb.broadinstitute.org/) (2020).
- 34. Bates, D. & Maechler, M. Matrix: Sparse and dense matrix classes and methods. *R*
- *package*,<http://cran.r-project.org/package=Matrix> (2010).
- 35. Rosseel, Y. lavaan: An R Package for Structural Equation Modeling. *Journal of Statistical*
- *Software* **48**, 1 36 (2012).
- 36. West, S.G., Taylor, A.B. & Wu, W. Model fit and model selection in structural equation modeling. in *Handbook of structural equation modeling.* 209-231 (The Guilford Press,
- New York, NY, US, 2012).
- 37. Mallard, T.T. *et al.* Multivariate GWAS of psychiatric disorders and their cardinal
- symptoms reveal two dimensions of cross-cutting genetic liabilities. *Cell Genomics* **2**, 100140 (2022).
- 38. Loehlin, J.C. The Cholesky approach: A cautionary note. *Behavior Genetics* **26**, 65-69 (1996).
- 39. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *American Journal of Human Genetics* **81**, 559-575 (2007).
- 40. Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex traits. *Nature Genetics* **51**, 1339-1348 (2019).
- 41. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nature Communications* **8**, 1826 (2017).
- 42. de Leeuw, C.A., Mooij, J.M., Heskes, T. & Posthuma, D. MAGMA: Generalized gene-set analysis of GWAS data. *PLOS Computational Biology* **11**, e1004219 (2015).
- 43. Li, M. *et al.* Integrative functional genomic analysis of human brain development and
- neuropsychiatric risks. *Science* **362**, eaat7615 (2018).

- 44. The GTEx Consortium *et al.* The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science* **369**, 1318-1330 (2020).
- 45. Wang, D. *et al.* Comprehensive functional genomic resource and integrative model for
- the human brain. *Science* **362**(2018).
- 46. Schmitt, Anthony D. *et al.* A compendium of chromatin contact maps reveals spatially
- active regions in the human genome. *Cell Reports* **17**, 2042-2059 (2016).
- 47. Szklarczyk, D. *et al.* The STRING database in 2023: protein-protein association networks
- and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids*
- *Research* **51**, D638-d646 (2023).
- 48. Bulik-Sullivan, B.K. *et al.* LD Score regression distinguishes confounding from
- polygenicity in genome-wide association studies. *Nature Genetics* **47**, 291-295 (2015).
- 49. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nature Genetics* **47**, 1236-1241 (2015).
- 50. Cuéllar-Partida, G. *et al.* Complex-Traits Genetics Virtual Lab: A community-driven web platform for post-GWAS analyses. *bioRxiv*, 518027 (2019).
- 51. Brown, Brielin C., Ye, Chun J., Price, Alkes L. & Zaitlen, N. Transethnic genetic-
- correlation estimates from summary statistics. *The American Journal of Human Genetics* **99**, 76-88 (2016).
- 52. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nature Genetics* **54**, 573-580 (2022).
- 53. Verma, A. *et al.* The Penn Medicine BioBank: Towards a genomics-enabled learning
- healthcare system to accelerate precision medicine in a diverse population. *Journal of*
- *Personalized Medicine* **12**, 1974 (2022).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.09.24307111;](https://doi.org/10.1101/2024.05.09.24307111) this version posted May 10, 2024. The copyright holder for this preprint

- 63. van der Kooij, M.A. *et al.* Role for MMP-9 in stress-induced downregulation of nectin-3 in hippocampal CA1 and associated behavioural alterations. *Nature Communications* **5**, 4995 (2014).
- 64. Liu, M. *et al.* Association studies of up to 1.2 million individuals yield new insights into
- the genetic etiology of tobacco and alcohol use. *Nature Genetics* **51**, 237-244 (2019).
- 65. Zhou, H. *et al.* Genome-wide association study identifies glutamate ionotropic receptor
- GRIA4 as a risk gene for comorbid nicotine dependence and major depression.
- *Translational Psychiatry* **8**, 208 (2018).
- 66. Xu, H. *et al.* Identifying genetic loci and phenomic associations of substance use traits: A
- multi-trait analysis of GWAS (MTAG) study. *Addiction* **118**, 1942-1952 (2023).
- 67. Stark, K.L. *et al.* Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. *Nature Genetics* **40**, 751-60 (2008).
- 68. Wu, Y. *et al.* Multi-trait analysis for genome-wide association study of five psychiatric
- disorders. *Translational Psychiatry* **10**, 209 (2020).
- 69. Charney, A.W. *et al.* Evidence for genetic heterogeneity between clinical subtypes of
- bipolar disorder. *Translational Psychiatry* **7**, e993-e993 (2017).
- 70. Romero, C. *et al.* Exploring the genetic overlap between twelve psychiatric disorders.
- *Nature Genetics* **54**, 1795-1802 (2022).
- 71. Martin, E., Schoeler, T., Pingault, J.-B. & Barkhuizen, W. Understanding the relationship
- between loneliness, substance use traits and psychiatric disorders: A genetically informed
- approach. *Psychiatry Research* **325**, 115218 (2023).

- 72. Paul, S.E. *et al.* Phenome-wide investigation of behavioral, environmental, and neural
- associations with cross-disorder genetic liability in youth of European ancestry. *medRxiv*,
- 2023.02.10.23285783 (2023).
- 73. Trelles, M.P. *et al.* Individuals with FOXP1 syndrome present with a complex
- neurobehavioral profile with high rates of ADHD, anxiety, repetitive behaviors, and sensory symptoms. *Molecular Autism* **12**, 61 (2021).
- 74. Drevets, W.C., Wittenberg, G.M., Bullmore, E.T. & Manji, H.K. Immune targets for
- therapeutic development in depression: Towards precision medicine. *Nature Reviews*
- *Drug Discovery* **21**, 224-244 (2022).
- 75. Tubbs, J.D., Ding, J., Baum, L. & Sham, P.C. Immune dysregulation in depression:
- Evidence from genome-wide association. *Brain, Behavior, & Immunity - Health* **7**, 100108 (2020).
- 76. Katrinli, S., Oliveira, N.C.S., Felger, J.C., Michopoulos, V. & Smith, A.K. The role of the
- immune system in posttraumatic stress disorder. *Translational Psychiatry* **12**, 313 (2022).
- 77. Wang, X.X. *et al.* Nectin-3 modulates the structural plasticity of dentate granule cells and long-term memory. *Translational Psychiatry* **7**, e1228-e1228 (2017).
- 78. Parekh, P.K., Johnson, S.B. & Liston, C. Synaptic mechanisms regulating mood state transitions in depression. *Annual Review of Neuroscience* **45**, 581-601 (2022).
- 79. Appelbaum, L.G., Shenasa, M.A., Stolz, L. & Daskalakis, Z. Synaptic plasticity and
- mental health: Methods, challenges and opportunities. *Neuropsychopharmacology* **48**,
- 113-120 (2023).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.09.24307111;](https://doi.org/10.1101/2024.05.09.24307111) this version posted May 10, 2024. The copyright holder for this preprint

- psychiatric disorders: Evidence from animal models. *Neurotoxicity Research* **19**, 286-307 (2011).
- 81. Lund, R.J. *et al.* Placental DNA methylation marks are associated with maternal
- depressive symptoms during early pregnancy. *Neurobiology of Stress* **15**, 100374 (2021).
- 82. McGill, M.G. *et al.* Maternal prenatal anxiety and the fetal origins of epigenetic aging.

Biological Psychiatry **91**, 303-312 (2022).

- 83. Jourdon, A., Scuderi, S., Capauto, D., Abyzov, A. & Vaccarino, F.M. PsychENCODE and
- beyond: Transcriptomics and epigenomics of brain development and organoids.
- *Neuropsychopharmacology* **46**, 70-85 (2021).
- 84. Kotov, R. *et al.* Validity and utility of Hierarchical Taxonomy of Psychopathology
- (HiTOP): I. Psychosis superspectrum. *World Psychiatry* **19**, 151-172 (2020).
- 85. Sorella, S. *et al.* Testing the expanded continuum hypothesis of schizophrenia and bipolar
- disorder. Neural and psychological evidence for shared and distinct mechanisms.
- *NeuroImage: Clinical* **23**, 101854 (2019).
- 86. Gallucci, G., Tartarone, A., Lerose, R., Lalinga, A.V. & Capobianco, A.M. Cardiovascular

risk of smoking and benefits of smoking cessation. *Journal of Thoracic Disease* **12**,

- 3866-3876 (2020).
- 87. Rosoff, D.B., Davey Smith, G., Mehta, N., Clarke, T.-K. & Lohoff, F.W. Evaluating the
- relationship between alcohol consumption, tobacco use, and cardiovascular disease: A
- multivariable Mendelian randomization study. *PLOS Medicine* **17**, e1003410 (2020).
- 88. Rostron, B.L. *et al.* Smokeless tobacco use and circulatory disease risk: a systematic
- review and meta-analysis. *Open Heart* **5**, e000846 (2018).

- 991 98. Bentley, A.R., Callier, S.L. & Rotimi, C.N. Evaluating the promise of inclusion of
- 992 African ancestry populations in genomics. *npj Genomic Medicine* **5**, 5 (2020).
- 993 99. Bick, A.G. *et al.* Genomic data in the All of Us Research Program. *Nature* **627**, 340-346
- 994 (2024).

995